Intellectual Property India Publishes Patent Application for 'A System And Method For Monitoring, Assessing, Preventing And Clinically Managing Hydroxyurea-Induced Adverse Drug Reactions In Pediatric Sickle Cell Disease Patients' Filed by Dr. Rajesh Hadia; Dr. Rajesh Maheshwari; Dr. Dipika Bhil; and Dr. Hemraj Singh Rajput

MUMBAI, India, March 13 -- Intellectual Property India has published a patent application (202621000768 A) filed by Dr. Rajesh Hadia; Dr. Rajesh Maheshwari; Dr. Dipika Bhil; and Dr. Hemraj Singh Rajput, Vadodara, Gujarat, on Jan. 5, for 'a system and method for monitoring, assessing, preventing and clinically managing hydroxyurea-induced adverse drug reactions in pediatric sickle cell disease patients.'

Inventor(s) include Dr. Rajesh Hadia; Dr. Rajesh Maheshwari; Dr. Dipika Bhil; and Dr. Hemraj Singh Rajput.

The application for the patent was published on March 13, under issue no. 11/2026.

According to the abstract released by the Intellectual Property India: "The present invention discloses a comprehensive system and method for monitori...